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Abstract
Dementia with Lewy bodies (DLB) is a clinically heterogeneous disorder with a substantial burden on healthcare.
Despite this, the genetic basis of the disorder is not well defined and its boundaries with other neurodegenerative
diseases are unclear. Here, we performed whole exome sequencing of a cohort of 1118 Caucasian DLB patients,
and focused on genes causative of monogenic neurodegenerative diseases. We analyzed variants in 60 genes
implicated in DLB, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and atypical parkinsonian or
dementia disorders, in order to determine their frequency in DLB. We focused on variants that have previously
been reported as pathogenic, and also describe variants reported as pathogenic which remain of unknown clinical
significance, as well as variants associated with strong risk. Rare missense variants of unknown significance were
found in APP, CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1, TBK1 and TIA1. Additionally, we identified a
pathogenic GRN p.Arg493* mutation, potentially adding to the diversity of phenotypes associated with this
mutation. The rarity of previously reported pathogenic mutations in this cohort suggests that the genetic overlap of
other neurodegenerative diseases with DLB is not substantial. Since it is now clear that genetics plays a role in DLB,
these data suggest that other genetic loci play a role in this disease.
Introduction
Dementia with Lewy bodies (DLB) is a neurodegenera-
tive disease that shares clinical and pathological features
with both Parkinson’s disease (PD) and Alzheimer’s disease
(AD). A disease most often occurring in the elderly demo-
graphic, it exhibits a varied clinical presentation that can in-
clude dementia, parkinsonism, visual hallucinations, REM
sleep behavior disorder, fluctuations in attention and alert-
ness, as well as autonomic and psychiatric dysfunction [49],
all described as clinical features of underlying synucleinopa-
thy. Similar to PD, the pathological hallmark of DLB is ac-
cumulation of alpha-synuclein in Lewy bodies (LBs) and
Lewy neurites, leading to consideration of these conditions
as different ends of the same clinico-pathological spectrum.
Lewy-related pathology in DLB can be found not only in
the brainstem, but also widespread in limbic and/or neocor-
tical regions [47]. Alzheimer pathology in the form of
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amyloid plaques and tau neurofibrillary tangles are fre-
quently found at autopsy [17].
At present, knowledge of the genetic etiology of DLB
is limited. Families with the disorder are rare, and SNCA
multiplications and point mutations have been shown to
cause disease in multiplex families of mixed Parkinson’s
disease and dementia [31, 63, 77]. Variants in PRNP [38]
and SNCB [55] have been reported in DLB, but their
pathogenicity has been questioned due to lack of replica-
tion, lack of segregation [55], or presence in healthy con-
trols [8]. DLB shares risk loci that are associated with
AD or PD, and we have recently shown the genetic cor-
relation between DLB and PD, and DLB and AD, is ap-
proximately equal when disregarding APOE [26]. The
APOE ε4 allele strongly predisposes to the development of
the disorder [13, 57, 64, 69], as do certain variants in the
GBA gene [53]. A non-synonymous variant in PLCG2 has
been proposed to confer protection from AD [62], and
more recently, DLB and frontotemporal dementia (FTD)
[71]. An association at the SNCA locus was identified,
which, interestingly, shows a differential association profile
in DLB than that seen in PD [13]. Furthermore, the first
genome-wide association study (GWAS) was recently pub-
lished, analyzing the genotyping data from 1743 DLB pa-
tients, a proportion of whom (745 samples) are also
included in this study. In a two-stage study design, the asso-
ciations at APOE, GBA and SNCA were replicated, and
novel loci reached suggestive levels of association [27]. It
has been proposed that rare variants in AD and PD causing
genes may also play a role in sporadic DLB. However, these
studies have been small, with sample sizes of approximately
100 cases [36, 37, 51]; it is thus uncertain whether these
findings are merely coincidental.
We performed exome sequencing of over 1000 DLB
patients to investigate the role of genetic variants in not
only AD and PD genes, but additionally in a collection
of approximately 40 disease genes established as causa-
tive of neurodegenerative diseases. The genetic variants
studied were those previously implicated in FTD with or
without amyotrophic lateral sclerosis (ALS); atypical par-
kinsonian disorders; and disorders with dementia as a
presenting feature.
As DLB is a heterogeneous disorder, and has overlap-
ping features with other diseases, accurate diagnosis relies
on the combination of clinical and pathological assess-
ments. To mitigate this issue as much as possible, the
DLB patients included in this study had a neuropatho-
logical diagnosis of DLB.
Methods
Cohort studied
We studied 1118 patients neuropathologically diagnosed
according to the 2005 McKeith diagnosis guidelines [49],
as meeting the criteria for ‘intermediate’ or ‘high’
likelihood DLB and self-reported as Caucasian. The
mean age at death in the cohort was 78.8 (±8.4) years
and the male to female ratio was 1.5.
Exome sequencing and data analysis
DNA was extracted from the cerebellum or frontal cortex
using standard methods [75]. Exome sequencing was per-
formed using Illumina’s Nextera Rapid Expanded Exome
capture (62Mb), or Agilent SureSelect Exome Capture Kit
(v4) and sequenced on Illumina’s HiSeq2500 using 100 bp
paired-end reads. On target average coverage of at least
30x was obtained for all included samples. Data analysis
was performed according to standard GATK (v3) best
practices [50] using a single informatics pipeline and per-
forming joint variant calling of single nucleotide variants
(SNVs) and short insertions and deletions (indels) across
all samples. In brief, sequencing reads were aligned to the
human reference genome (GRCh37/hg19) using bwa-
mem (v0.7.12), duplicate reads were flagged using sambla-
ster (v0.1.21), and realignment around indels and base
quality scores were recalibrated using GATK. Variant re-
calibration was performed using GATK’s variant quality
score recalibration (VQSR) [21, 70]. Variants that did not
meet the VQSR threshold of 99.9 were excluded. Individ-
ual genotypes with a phred-scaled quality score below 20
and with coverage below 8 were set to missing. Variants
were included only if they had a high call rate in both cap-
ture kits (genotyped in ≥90% of samples). Annotation of
variants was performed with snpEff (v4.2) [15] and
dbNSFP v2.9 [44] using GRCh37/hg19 as reference.
Sample quality control (QC)
Sample quality control metrics were generated using
PLINK 1.9 [58]. Population structure was analysed using
principal component analysis, and samples that did not
cluster with the European population of the 1000 Genomes
dataset were removed from analysis. Concordance between
reported and genotype sex was performed for each sample
to remove those with a discordant sex assignment. Samples
with inconsistent heterozygosity rates, or that were shown
to be related or duplicated were excluded. Due to linkage
disequilibrium, population structure and genotyping error,
we removed an individual from a pair of samples using a
proportion of identity by descent threshold of ≥0.1875 [3].
After QC measures, we analyzed variants from 1004 DLB
patients. The locations from which the DLB samples were
sourced can be found in Additional file 1: Table S1.
Neurodegenerative disease genes
Fifty-seven genes were selected based on their role in
monogenic forms of neurodegenerative diseases including
AD, PD, FTD and related Mendelian disorders featuring
parkinsonism or dementia. Due to its relevance to DLB,
we also report on variants in GBA and APOE, as well as
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the PLCG2 p.Pro522Arg variant. A full list of the studied
genes can be found in Additional file 2: Table S2.
We focused on variants that were amino acid chan-
ging; or that fell in splice donor/acceptor sites; in splice
regions, or in 5′ or 3′ untranslated regions.
A literature search was conducted for each disease-
causing gene studied in order to identify previously re-
ported pathogenic mutations. This included primary lit-
erature reports; supplementary information; the Human
Gene Mutation Database [66]; the Online Mendelian In-
heritance in Man website [2]; the AD & FTD, and PD
mutation databases [20]; and Clinvar [39]. Population
variant frequency was determined using gnomAD (v2.1),
a genomic database consisting of variants from 125,748
exomes and 15,708 genomes [34, 41].
The maximum frequency that a known pathogenic vari-
ant occurs in a large cohort of a disease of interest allows
for an estimation of the maximum tolerated frequency of a
pathogenic variant for that disease [74]. As the genetics of
DLB is yet to be fully delineated, we used Alzheimer’s dis-
ease to estimate a maximum tolerated allele count for a
pathogenic variant to occur in the gnomAD database, im-
plemented using the alleleFrequencyApp http://cardiodb.
org/allelefrequencyapp/ [74]. This was used as a conserva-
tive approximation of maximum tolerated variant frequen-
cies for pathogenic mutations in the general population for
a disease such as AD.
Reported variants were also analysed for their frequency
in 432 control individuals from the Healthy Exomes (HEX)
dataset, who died aged 60 or over, without any disease-
associated neuropathology [29, 28].
APOE genotyping
Given the difficulty in sequencing the APOE locus, the
APOE haplotype was confirmed in samples where DNA
was available (n = 758 samples). APOE haplotype geno-
typing was conducted using enzyme restriction, as previ-
ously described [29].
Sanger sequencing
Candidate variants were confirmed by Sanger sequencing
when DNA was available. DNA was amplified by polymer-
ase chain reaction using Roche FastStart PCR Master Mix
(Roche Diagnostics Corp) and sequenced with Applied
Biosystems BigDye terminator version 3.1 sequencing
chemistry in an ABI3730XL genetic analyzer as per manu-
facturer’s instructions (Applied Biosystems). Primers are
available upon request. The sequences were analysed
using Sequencher software version 4.2 (Gene Codes).
Results
We performed a detailed analysis of the genetic variability
of 57 genes shown previously to cause neurodegenerative
diseases in over 1000 DLB cases. Furthermore, we also
report on GBA and APOE, well established risk genes for
DLB, as well as the recently reported protective PLCG2
p.Pro522Arg variant.
We identified a pathogenic nonsense mutation in GRN,
p.Arg493* (ENST00000053867), in one patient. This vari-
ant was confirmed by Sanger sequencing. In addition, we
identified previously reported mutations that, due to their
low frequency in the general population, have uncertain
clinical significance (Table 1). No previously reported
pathogenic homozygous variants were identified in genes
that cause neurodegenerative disease with autosomal re-
cessive inheritance. As the data was not phased, com-
pound heterozygous variants could not be completely
assessed.
GRN p.Arg493*
The patient with the p.Arg493* GRN mutation had a med-
ical history that included a stroke, and previous surgical
evacuation of a subdural haematoma, as well as a family
history of AD in a parent and a sibling, with onset in the
seventh decade. The presenting symptom was episodes of
confusion, and a CT scan showed moderate cerebral and
cerebellar atrophy with a lacunar infarct in the left external
capsule. Subsequent symptoms included memory loss, dis-
orientation, altered gait, stooped posture, right-sided rigid-
ity and visual hallucinations. Impaired smooth pursuit, left
hemiparesis, left spasticity, right-sided rigidity, and a slight
parkinsonian tremor of the left hand were also reported.
The patient was severely demented and scored 3/30 on the
Mini Mental State Examination (MMSE) in an assessment
conducted at 83 years, approximately 2 years before death.
Macroscopically, the right convexity of the brain showed
very marked asymmetrical atrophy of the frontal, temporal
and parietal lobes, with knife-edge atrophy at the frontal and
temporal poles, and mild atrophy of the right occipital lobe.
There were no focal lesions. Pathological examination with
immunohistochemical staining for alpha-synuclein protein
showed a single LB in the substantia nigra; very infrequent
Lewy bodies in multiple cortical areas; sparse LBs in the an-
terior cingulate, entorhinal and transentorhinal cortices; and
no LBs in the amygdala. Thioflavin S methods showed fre-
quent diffuse amyloid plaques in neocortical areas. Very in-
frequent neurofibrillary tangles were present in the nucleus
basalis of Meynert, hypothalamus and entorhinal cortex,
and were absent from all neocortical areas examined. Immu-
nohistochemical staining for abnormal tau protein identified
frequent dot-like features and diffusely stained neurons in
the entorhinal cortex, transentorhinal cortex, CA1 and subi-
culum of the hippocampus and the parahippocampal gyrus.
There were sparse argyrophilic grains in the amygdala, ento-
rhinal cortex and area CA1 of the subiculum. Immunohisto-
chemical staining for ubiquitin showed moderate densities
of short neuropil threads and dots, as well as sparse to mod-
erate densities of small cytoplasmic inclusions in layer II of
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frontal and temporal neocortical regions. Following the
identification of the mutation, the sample was stained for
TDP-43 and revealed inclusions in frontal and temporal
lobes. Sections stained immunohistochemically for phos-
phorylated TDP-43 protein showed immunoreactive dys-
trophic puncta, neurites and perikaryal cytoplasmic
inclusions within layer II of frontal and temporal neocortical
areas, as well as the amygdala, hippocampal CA1 region,
and entorhinal cortex. These features reached moderate to
frequent densities in the frontal and temporal neocortex.
Established risk factors for DLB
No homozygous Gaucher disease causing variants were
identified in GBA. Table 2 details variants found in GBA
that had a call-rate of 90% or greater. Two variants,
p.Glu365Lys and p.Asn409Ser were over-represented in
DLB compared to the gnomAD database. Of note, 2
homozygous carriers of p.Glu365Lys were identified and
a novel variant, p.Asn409del, was identified in 1 patient
in the cohort.
APOE haplotypes were independently genotyped in 758
DLB samples where DNA was available. Of this subset of
samples, the ε4 allele frequency was 48.6%, in keeping with
the prevalence of this allele in previous reports [64, 69].
Potentially pathogenic variants
We used Alzheimer’s disease genetics as a model in order
to apply an approximate threshold for the tolerated occur-
rence of pathogenic AD mutations in gnomAD. We applied
an AD prevalence of 1/79 (Alzheimer Society Dementia re-
port, 2014); a maximum estimated disease-causing MAF of
0.0012; and a very conservative penetrance threshold of 0.5.
The maximum tolerated frequency for a pathogenic allele
for AD using the allele number of a variant genotyped in
the entire gnomAD European (non-Finnish) population
was 1.5556 × 10− 5, or five alleles. This is a very conservative
approximation, likely to be too high since AD is more
prevalent than DLB, however since the genetic architecture
of DLB still remains largely unresolved, we used AD as an
approximation. In Table 1 we describe previously reported
variants of unknown clinical significance that were present
in 5 or less Europeans in the gnomAD database. None of
these variants were detected in the control individuals from
the HEX dataset. These variants were identified in APP,
CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1,
TBK1 and TIA1. Variants were reported in Table 1 if the
evidence for pathogenicity was moderate, such as having
unproven segregation with disease; eliciting a different
amino acid change than was previously reported; identified
in a gene that has not been replicated as causative for dis-
ease; or if the variant has also been identified in a control
subject. Table 1 also shows variants not present in Euro-
peans in gnomAD that affect the same or an adjacent
amino acid as previously reported in disease. Table 3 lists
variants identified in multiple DLB cases and with 5 or less
alleles in gnomAD.
Variants that have previously been reported in disease,
but were more frequent in the general population, thus
less likely to be fully penetrant, disease-causing alleles,
are reported in Additional file 3: Table S3. These include
variants such as SNCA p.His50Gln, which is present in
19 Europeans in gnomAD, and whose pathogenicity has
been disputed [10].
Genes previously reported in DLB
We investigated variants in genes that have been re-
ported as causative of DLB - PRNP and SNCB - as well
as a gene in which a variant was recently reported as
protective for DLB - PLCG2.
The previously identified PRNP p.Met232Arg [38]
variant was not present in our cohort, and there were no
other previously reported pathogenic variants in PRNP
in our data. It is therefore unlikely that PRNP mutations
cause sporadic DLB in the European population.
The SNCB p.Val70Met and p.Pro123His variants reported
to predispose to DLB [55] were also not found in our cohort
of DLB cases, suggesting that if they play a role in DLB, they
may be population specific risk factors. In our cohort, no
non-synonymous variants were found in the SNCB gene,
even though the entire gene was adequately covered.
A variant in PLCG2, p.Pro522Arg, has been reported to
reduce the risk of DLB, AD and FTD [71]. This variant
was identified in 18 DLB cases (MAF 0.0089), which is
similar to the frequency found in gnomAD non-Finnish
Europeans (MAF 0.0087).
TREM2
TREM2 is the second strongest genetic risk factor for
AD, an effect largely driven by the p.R47H variant. In our
data, the p.Arg47His variant, which was successfully se-
quenced in 667 of the 1004 samples, had a MAF 0.00299,
which is similar to the frequency in NFEs in gnomAD
(MAF 0.002466). The p.Arg62His variant also had a simi-
lar MAF in DLB (0.0142), compared to Europeans in the
gnomAD database (0.0112). Likewise, the frequency of
p.Thr96Lys and p.Leu211Pro variants was similar in DLB
patients and gnomAD, (MAF 0.000991 versus 0.00101,
and MAF 0.000992 versus 0.00113), respectively. No
homozygous variants in TREM2 were identified.
Discussion
We present a comprehensive analysis of rare genetic
variability in an extensive number of neurodegenerative
disease-causing genes in a large cohort of patients diag-
nosed with DLB. We used state-of-the-art analytical ap-
proaches with well-established quality control criteria
that allowed us to identify genetic variability and esti-
mate its contribution to disease.
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Mutations in GRN cause FTD [7, 19], and the most
commonly reported pathogenic mutation in GRN is
p.Arg493* [59]. The patient described here lacked promin-
ent clinical signs of FTD, such as changes in behavior, per-
sonality, or language impairment. Severe dementia,
parkinsonism and visual hallucinations were present, and
led to the suggested clinical diagnosis of Alzheimer’s dis-
ease or mixed vascular dementia, with a final neuropatho-
logical diagnosis of Alzheimer’s disease, dementia with
Lewy bodies and argyrophilic grain disease. Substantial
phenotypic variability has been described in patients with
a GRN p.Arg493* mutation. In 34 patients identified with
this mutation, 25 had a diagnosis of FTD; 4 of primary
progressive aphasia; 3 of corticobasal syndrome and 3 of
Alzheimer’s disease. Age at onset ranged from 44 to 69,
and the most common initial symptom was a change in
personality or executive dysfunction (25/33 patients), with
subsequent language impairment occurring in 26 of 33 pa-
tients. Fourteen out of thirty patients had parkinsonism
and 10% had visual hallucinations [59]. This mutation has
also been found in 4 patients with sporadic Alzheimer’s
disease [24].
An overlap between FTD and DLB has been shown both
clinically and neuropathologically. Several patients have
been identified that simultaneously met clinical criteria for
both FTD and DLB [16, 52], or that presented clinically
with FTD, but at autopsy had DLB [11, 61]. Concomitant
TDP-43 and alpha-synuclein pathology can be found in
27–60% of DLB cases at autopsy [4, 17, 48]. In general,
GRN mutations result in disease with clinical heterogeneity
[40, 72, 73], and it is possible that overlaps between DLB
and FTD may be connected to variation in GRN. It is also
possible that hallucinations and delusions in GRN carriers
may cause a misdiagnosis of DLB [9]. An FTD case harbor-
ing the GRN p.Thr382fs mutation showed a phenotype re-
sembling DLB, with fluctuations in cognition,
parkinsonism and visual hallucinations [5]. Furthermore,
alpha-synuclein and TDP-43 pathologies were found in a
subset of brains of patients with a GRN mutation [42]. A
small study in 58 DLB cases showed that together, rare var-
iants in GRN are associated with DLB [37], although this is
yet to be independently replicated. A recent study identi-
fied 9 heterogeneous FTLD cases with coexisting Lewy
body pathology Braak stage ≥ IV, comprising 7% of the co-
hort. Two of the 9 cases had a secondary diagnosis of DLB,
and a further 2 had GRN mutations [25]. Progranulin and
β-amyloid have been shown to co-localize in plaques in
DLB, suggesting a possible biological association between
these two aggregated proteins [60]. However, there are
often multiple concomitant pathologies that are identified
in neurodegenerative disease, and so the observation of
TDP-43 with Lewy and amyloid pathology could simply be
coincidental multi-morbidity of simultaneous pathologies
that coexist in the ageing brain [6]. After the identification
of the GRN mutation, additional clinicopathological infor-
mation was reviewed to assess this case. The histopatho-
logical findings of the p.Arg493* carrier revealed Lewy
bodies; amyloid plaques; argyrophilic grains; ubiquitin posi-
tive inclusions; tau staining, and when reanalysed, TDP-43
pathology. The medical history reported the occurrence of
a stroke, which was also confirmed by a CT scan, however
no further clinical information was available. Taken to-
gether, these facts add to the difficulty in classifying these
more complex forms of disease. Particularly in archive
cases where the neuropathology assessment did not origin-
ally include staining for TDP-43.
We identified possible pathogenic variants in other genes
linked to the FTD-ALS spectrum of disease. A variant in
TIA1, p.Pro362Leu, suggested to be causative of ALS/FTD,
was found in 1 DLB patient in the cohort. TIA1 encodes
an RNA-binding protein, and this variant was reported in a
pair of second degree relatives with ALS/FTD, as well as a
clinically symptomatic, but non-demented relative. An in-
creased burden of rare heterozygous TIA1 mutations in a
larger ALS/FTD cohort was reported [45]. In two neuro-
pathologically diagnosed DLB cases, we found two variants
in TBK1 that affected the same amino acid: p.Arg384Trp
and p.Arg384Gln. This amino acid has been found to be al-
tered in a sporadic Sardinian ALS case (p.Arg384Thr) [12]:
a variant not present in gnomAD, but whose pathogenicity
is unconfirmed. It is intriguing that two DLB cases were
identified with variants that affect the same amino acid.
Table 3 Variants found in more than 1 DLB case, that were present in 5 or less individuals from the gnomAD exome dataset of
non-Finnish Europeans
Gene Transcript Variant Number of DLB cases GnomAD NFE AC (Total NFE AN)
PARK2 ENST00000366898 p.Gln440Arg 2 1 (112822)
VPS13C ENST00000261517 p.Ile288Met 2 4 (112094)
TUBA4A ENST00000248437 p.Val181Met 2 5 (113764)
DNAJC6 ENST00000371069 p.Val632Ala 2 0 (83222)
VPS35 ENST00000299138 p.Arg499His 2 4 (113646)
All variants were identified in the heterozygous state. gnomAD NFE Non-Finnish European, AC Allele Count, AN Allele Number
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These variants are present in gnomAD (MAFs 0.0000213
and 0.0000851, respectively). At present, their contribution
to DLB is unclear.
From the perspective of AD related genetics, we identified
a variant of unknown significance in APP - p.Glu674Lys -
in a DLB case, a substitution of a negatively charged amino
acid to a positively charged amino acid at the 3rd residue of
the ß-amyloid peptide. This variant was not present in the
gnomAD database, and affects an adjacent amino acid to
that previously described. The p.Ala673Val was shown to
cause early onset Alzheimer’s disease in the homozygous
state, whereas heterozygous individuals in the family were
unaffected [22]. A different amino acid change at the same
position, p.Ala673Thr, has been reported in a patient with-
out AD [56], and predicted as non pathogenic due to non
segregation with disease in a family [18]. Furthermore, this
variant was shown to be protective against Alzheimer’s dis-
ease in the Icelandic population, where it resulted in a re-
duction of beta-secretase cleavage in vitro [32].
We have also looked at strong risk modulating genes:
GBA, TREM2, APOE and PLCG2. If at GBA and APOE
we saw evidence of increased frequency in the previously
reported variants, we did not observe such a finding at
TREM2 or PLCG2, with both showing frequencies that
are identical to those found in the general population.
We have also identified a number of possible pathogenic
mutations in several other genes studied here (Table 1).
The design of this study does not allow variant pathogen-
icity to be unequivocally established, and, in this way, we
report these variants to allow future studies to attempt
confirmation of these findings.
In summary, we provide the first large-scale
characterization of rare genetic variability in the most
relevant neurodegenerative disease-causing genes in DLB.
Our findings suggest that mutations in genes known to
cause other neurodegenerative diseases are not a common
cause of DLB.
Supplementary information
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1186/s40478-020-0879-z.
Additional file 1: Table S1. Sources of samples. Research groups,
clinical teams and brain banks where the DLB samples included in this
study were collected from.
Additional file 2: Table S2. Neurodegenerative disease-causing genes
and DLB risk genes analysed in this study. Genes known to cause neuro-
degenerative diseases are presented according to the mode of inherit-
ance of the respective mendelian disease. Genes such as PARK2, FBXO7,
SYNJ1, and DNAJC6, among others, are commonly referred to as parkin-
son’s disease genes, although the clinical and pathological characteristics
may be atypical in some cases. FTD/ALS - frontotemporal dementia/
Amyotrophic lateral sclerosis, CADASIL - Cerebral arteriopathy, autosomal
dominant, with subcortical infarcts and leukoencephalopathy, CARASIL -
Cerebral arteriopathy, autosomal recessive, with subcortical infarcts and
leukoencephalopathy *Both TMEM230 and DNAJC13 have been hypothe-
sised to be the cause of Parkinson’s disease in the same family.
Additional file 3: Table S3. Variants identified in the studied DLB
cohort that have been previously reported in disease and have a
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European allele number. GnomAD Total MAF = gnomAD all populations
minor allele frequency.
Acknowledgements
This work was supported in part by the National Institutes of Neurological
Disease and Stroke and by the Alzheimer’s Society. TO was supported by a
scholarship from the Lewy Body Society. We would like to thank Dr. Daniela
Hansen from the Reta Lila Weston Institute at the Institute of Neurology,
UCL. For the neuropathologically confirmed samples from Australia, tissues
were received from the Sydney Brain Bank which is supported by
Neuroscience Research Australia and the University of New South Wales. We
acknowledge the Oxford Brain Bank, supported by the Medical Research
Council (MRC), Brains for Dementia Research (BDR) (Alzheimer Society and
Alzheimer Research UK), Autistica UK and the NIHR Oxford Biomedical
Research Centre. We would like to thank the South West Dementia Brain
Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of
the Brains for Dementia Research programme, jointly funded by Alzheimer’s
Research UK and Alzheimer’s Society and is supported by BRACE (Bristol
Research into Alzheimer’s and Care of the Elderly) and the Medical Research
Council. Regarding the brain samples and/or bio samples that were obtained
from The Netherlands Brain Bank, Netherlands Institute for Neuroscience,
Amsterdam (open access: www.brainbank.nl): all Material has been collected
from donors for or from whom a written informed consent for a brain
autopsy and the use of the material and clinical information for research
purposes had been obtained by the NBB. This study was also partially
funded by the Canadian Consortium on Neurodegeneration in Aging
(Rogaeva and St. George-Hyslop). The Nottingham Genetics Group is sup-
ported by ARUK and The Big Lottery Fund. The effort from Columbia Univer-
sity was supported by the Taub Institute, the Panasci Fund, the Parkinson’s
Disease Foundation, and NIH grants NS060113 (L. Clark), P50AG008702 (P.I.
Scott Small), P50NS038370 (P.I. R. Burke), and UL1TR000040 (P.I. H. Ginsberg).
O.A.R. is supported by the Michael J. Fox Foundation, NINDS R01# NS078086.
The Mayo Clinic Jacksonville is a Morris K. Udall Parkinson’s Disease Research
Center of Excellence (NINDS P50 #NS072187) and is supported by The Little
Family Foundation and by the Mangurian Foundation Program for Lewy
Body Dementia research and the Alzheimer Disease Research Center (P50
AG016547). The Brain and Body Donation Program (TGB) has been supported
by the National Institute of Neurological Disorders and Stroke (U24
NS072026 National Brain and Tissue Resource for Parkinson’s Disease and Re-
lated Disorders), the National Institute on Aging (P30 AG19610 Arizona Alz-
heimer’s Disease Core Center), the Arizona Department of Health Services
(contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomed-
ical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Ari-
zona Parkinson’s Disease Consortium) and the Michael J. Fox Foundation for
Parkinson’s Research. The work from the Mayo Clinic Rochester is supported
by the National Institute on Aging (P50 AG016574 and U01 AG006786). This
work has received support from The Queen Square Brain Bank at the UCL In-
stitute of Neurology; where TL is funded by an ARUK senior fellowship. Some
of the tissue samples studied were provided by the MRC London Neurode-
generative Diseases Brain Bank and the Brains for Dementia Research project
(funded by Alzheimer’s Society and ARUK). This research was supported in
part by both the NIHR UCLH Biomedical Research Centre and the Queen
Square Dementia Biomedical Research Unit. This work was supported in part
by the Intramural Research Program of the National Institute on Aging, Na-
tional Institutes of Health, Department of Health and Human Services; project
AG000951-12. The University of Pennsylvania case collection is funded by the
Penn Alzheimer’s Disease Core Center (AG10124) and the Penn Morris K.
Udall Parkinson’s Disease Research Center (NS053488). The authors would like
to thank the Genome Aggregation Database and the groups that provided
exome and genome variant data for comparison. A full list of contributing
groups can be found at https://gnomad.broadinstitute.org/. Tissue samples
from UCSD are supported by NIH grant AG05131. The authors thank the
brain bank GIE NeuroCEB, the French program “Investissements d’avenir”
(ANR-10-IAIHU-06). PJT and LM are supported by the Helsinki University Cen-
tral Hospital, the Sigrid Juselius Foundation, the Folkhälsan Research Founda-
tion and the Finnish Academy. HZ is a Wallenberg Academy Fellow and is
Orme et al. Acta Neuropathologica Communications             (2020) 8:5 Page 8 of 11
further supported by the UK Dementia Research Institute at UCL, the Euro-
pean Research Council and the Swedish Research Council.
Authors’ contributions
JB and AS conceived the study. JB, AS, RG and TO contributed to study
design. JB, DH, CKR and AS contributed to data generation. JB and TO
contributed to data analysis. JB, RG and TO contributed to data
interpretation. TO drafted the manuscript and JB and RG performed critical
review and additional writing. All other authors contributed samples. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1UK Dementia Research Institute at UCL and Department of Molecular
Neuroscience, Institute of Neurology, University College London, London, UK.
2Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda,
MD, USA. 3Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
4Center for Neurodegenerative Science, Van Andel Research Institute, Grand
Rapids, Michigan, USA. 5Neuroscience Research Australia, Sydney, Australia
and School of Medical Sciences, Faculty of Medicine, University of New
South Wales, Sydney, Australia. 6Nuffield Department of Clinical
Neurosciences, Oxford Parkinson’s Disease Centre, University of Oxford,
Oxford, UK. 7Taub Institute for Alzheimer Disease and the Aging Brain and
Department of Pathology and Cell Biology and Neurology, Columbia
University Medical Center, New York, NY, USA. 8Department of Neurology
and Alzheimer Center, Neuroscience Campus Amsterdam, VU University
Medical Center, Amsterdam, the Netherlands. 9Department of Medicine, Tanz
Centre for Research in Neurodegenerative Diseases, University of Toronto,
Toronto, ON, Canada. 10Clinical Memory Research Unit, Institution of Clinical
Sciences Malmö, Lund University, Lund, Sweden. 11UK Dementia Research
Institute at UCL and Department of Molecular Neuroscience, Institute of
Neurology, University College London, London, UK. 12Clinical Neurochemistry
Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy
at the University of Gothenburg, Mölndal, Sweden. 13Human Genetics,
School of Life Sciences, University of Nottingham, Nottingham, UK.
14Department of Basic and Clinical Neuroscience and Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, London, UK. 15Queen
Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of
Neurology, London, UK. 16Parkinson’s Disease & Movement Disorders Unit,
Neurology Service, Clinical Neuroscience Institute (ICN), Hospital Clínic,
Institut de Neurociències, University Universitat de Barcelona, IDIBAPS,
Barcelona, Catalonia, Spain. 17Department of Pathology and Laboratory
Medicine, Center for Neurodegenerative Disease Research, Perelman School
of Medicine at the University of Pennsylvania, 3600 Spruce Street,
Philadelphia, USA. 18Banner Sun Health Research Institute, 10515 W Santa Fe
Drive, Sun City, AZ 85351, USA. 19Sorbonne Université, Université Pierre et
Marie Curie-Paris 06, Inserm, Centre National de la Reserche Scientifique, and
Institute du Cerveau et de la Moelle épinière, Paris, France. 20Assistance
Publique Hôpitaux de Paris, Hôpital de la Salpêtrière, Département de
Génétique et Cytogénétique, Paris, France. 21Division of Neurosciences and
Laboratory of Neurogenetics, National Institute on Aging/NIH, Bethesda, MD,
USA. 22Neurology Service, University of Coimbra Hospital, Coimbra, Portugal.
23Memory Unit, Department of Neurology, University Hospital Mutua de
Terrassa, University of Barcelona, Terrassa, Barcelona, Spain. 24Centro de
Investigación Biomédica en Red Enfermedades Neurodegenerativas
(CIBERNED), Madrid, Spain. 25Translational Immunology, Research Programs
Unit, Department of Neurology, Helsinki University Hospital, University of
Helsinki, Helsinki, Finland. 26Department of Pathology, University of Helsinki
and HUSLAB, Helsinki University Hospital, Helsinki, Finland. 27Department of
Neuropathology and Neurosurgery, Helsinki University Hospital and
University of Helsinki, Helsinki, Finland. 28Neurology Department, Mayo Clinic,
Rochester, MN, USA. 29Department of Psychiatry and Department of
Psychology, Mayo Clinic, Jacksonville, FL, USA. 30UK Dementia Research
Institute at Cardiff and MRC Centre for Neuropsychiatric Genetics and
Genomics, School of Medicine, Cardiff University, Cardiff, UK. 31Department
of Neurology, Mayo Clinic, Jacksonville, FL, USA. 32Department of Neurology,
Washington University School of Medicine, Saint Louis, MO, USA. 33Division
of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine
and Health, University of Manchester, Manchester, UK. 34Genetics and
Pharmacogenomics, Merck & Co., Inc., West Point, PA, USA.
Received: 20 November 2019 Accepted: 3 January 2020
References
1. Adib-Samii P, Brice G, Martin RJ, Markus HS (2010) Clinical spectrum of
CADASIL and the effect of cardiovascular risk factors on phenotype: study in
200 consecutively recruited individuals. Stroke. 41:630–634
2. Amberger J, Bocchini CA, Scott AF, Hamosh A (2009) McKusick’s Online
Mendelian Inheritance in Man (OMIM®). Nucleic Acids Res 37:D793–D796
3. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan
KT (2010) Data quality control in genetic case-control association studies.
Nat Protoc. 5:1564–1573
4. Arai T, Mackenzie IRA, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K et al
(2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with
Lewy bodies. Acta Neuropathol. 117:125–136
5. Arosio B, Abbate C, Galimberti D, Rossi PD, Inglese S, Fenoglio C et al (2013)
GRN Thr272fs clinical heterogeneity: a case with atypical late onset
presenting with a dementia with Lewy bodies phenotype. J Alzheimers Dis.
35:669–674
6. Attems J (2017) The multi-morbid old brain. Acta Neuropathol. 134:169–170
7. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm
C et al (2006) Mutations in progranulin cause tau-negative frontotemporal
dementia linked to chromosome 17. Nature. 442:916–919
8. Beck J, Collinge J, Mead S (2012) Prion protein gene M232R variation is
probably an uncommon polymorphism rather than a pathogenic mutation.
Brain 135(Pt 2):e209 author reply e210
9. Benussi A, Padovani A, Borroni B (2015) Phenotypic Heterogeneity of
Monogenic Frontotemporal Dementia. Front Aging Neurosci. 7:171
10. Blauwendraat C, Kia DA, Pihlstrøm L, Gan-Or Z, Lesage S, Gibbs JR et al
(2018) Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in
Parkinson’s disease. Neurobiol Aging 64:159.e5–159.e8
11. Bonner LT, Tsuang DW, Cherrier MM, Eugenio CJ, Du Jennifer Q, Steinbart EJ
et al (2003) Familial dementia with Lewy bodies with an atypical clinical
presentation. J Geriatr Psychiatry Neurol. 16:59–64
12. Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G et al
(2016) TBK1 is associated with ALS and ALS-FTD in Sardinian patients.
Neurobiol Aging 43:180.e1–180.e5
13. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V et al
(2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal
dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet
23:6139–6146
14. Choi JC, Kang S-Y, Kang J-H, Park J-K (2006) Intracerebral hemorrhages in
CADASIL. Neurology. 67:2042–2044
15. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L et al (2012) A
program for annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster
strain w1118; iso-2; iso-3. Fly 6:80–92
16. Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA (2008)
Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn
Behav Neurol. 21:157–163
17. Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ et al (2013)
Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with
Lewy bodies. J Neuropathol Exp Neurol. 72:1203–1212
18. Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FLM, Mitra RD et al
(2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-
onset Alzheimer’s disease families. PLoS One. 7:e31039
19. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D et al (2006)
Null mutations in progranulin cause ubiquitin-positive frontotemporal
dementia linked to chromosome 17q21. Nature. 442:920–924
20. Cruts M, Theuns J, Van Broeckhoven C (2012) Locus-specific mutation
databases for neurodegenerative brain diseases. Hum Mutat. 33:1340–1344
21. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al (2011)
A framework for variation discovery and genotyping using next-generation
DNA sequencing data. Nat Genet. 43:491–498
22. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G et al (2009)
A recessive mutation in the APP gene with dominant-negative effect on
amyloidogenesis. Science. 323:1473–1477
Orme et al. Acta Neuropathologica Communications             (2020) 8:5 Page 9 of 11
23. Falchetti A, Di Stefano M, Marini F, Del Monte F, Gozzini A, Masi L et al
(2005) Segregation of a M404V mutation of the p62/sequestosome 1 (p62/
SQSTM1) gene with polyostotic Paget’s disease of bone in an Italian family.
Arthritis Res Ther. 7:R1289–R1295
24. Fernández MV, Kim JH, Budde JP, Black K, Medvedeva A, Saef B et al (2017)
Analysis of neurodegenerative Mendelian genes in clinically diagnosed
Alzheimer Disease. PLoS Genet. 13:e1007045
25. Forrest SL, Crockford DR, Sizemova A, McCann H, Shepherd CE, McGeachie
AB et al (2019) Coexisting Lewy body disease and clinical parkinsonism in
frontotemporal lobar degeneration. Neurology Available from: https://doi.
org/10.1212/WNL.0000000000007530
26. Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez
DG et al (2016) Genome-wide analysis of genetic correlation in dementia
with Lewy bodies, Parkinson’s and Alzheimer’s diseases. Neurobiol Aging 38:
214.e7–214.e10
27. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD et al
(2018) Investigating the genetic architecture of dementia with Lewy bodies: a
two-stage genome-wide association study. Lancet Neurol. 17:64–74
28. Guerreiro R, Sassi C, Gibbs JR, Edsall C, Hernandez D, Brown K, et al. A
comprehensive assessment of benign genetic variability for
neurodegenerative disorders. bioRxiv, 2018.
29. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein
E by gene amplification and cleavage with HhaI. J Lipid Res. 31:545–548
30. Hocking LJ, Lucas GJA, Daroszewska A, Cundy T, Nicholson GC, Donath J
et al (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of
bone: genotype phenotype correlation, functional analysis, and structural
consequences. J Bone Miner Res. 19:1122–1127
31. Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan C-F et al (2008)
Patients homozygous and heterozygous for SNCA duplication in a family
with parkinsonism and dementia. Arch Neurol. 65:514–519
32. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al
(2012) A mutation in APP protects against Alzheimer’s disease and age-
related cognitive decline. Nature. 488:96–99
33. Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C et al
(1997) Strong clustering and stereotyped nature of Notch3 mutations in
CADASIL patients. Lancet. 350:1511–1515
34. Karczewski KJ, Francioli LC, Tiao G, Cummings BB (2019) Variation across
141,456 human exomes and genomes reveals the spectrum of loss-of-
function intolerance across human protein-coding genes. BioRxiv Available
from: https://www.biorxiv.org/content/10.1101/531210v2.abstract
35. Kenna KP, McLaughlin RL, Byrne S, Elamin M, Heverin M, Kenny EM et al
(2013) Delineating the genetic heterogeneity of ALS using targeted high-
throughput sequencing. J Med Genet. 50:776–783
36. Keogh MJ, Kurzawa-Akanbi M, Griffin H, Douroudis K, Ayers KL, Hussein RI et al
(2016) Exome sequencing in dementia with Lewy bodies. Transl Psychiatry. 6:e728
37. Keogh MJ, Wei W, Wilson I, Coxhead J, Ryan S, Rollinson S et al (2017) Genetic
compendium of 1511 human brains available through the UK Medical
Research Council Brain Banks Network Resource. Genome Res. 27:165–173
38. Koide T, Ohtake H, Nakajima T, Furukawa H, Sakai K, Kamei H et al (2002) A
patient with dementia with Lewy bodies and codon 232 mutation of PRNP.
Neurology. 59:1619–1621
39. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S et al (2016)
ClinVar: public archive of interpretations of clinically relevant variants.
Nucleic Acids Res. 44:D862–D868
40. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A
et al (2008) Phenotype variability in progranulin mutation carriers: a clinical,
neuropsychological, imaging and genetic study. Brain. 131:732–746
41. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T et al (2016)
Analysis of protein-coding genetic variation in 60,706 humans. Nature. 536:
285–291
42. Leverenz JB, Yu CE, Montine TJ, Steinbart E, Bekris LM, Zabetian C et al
(2007) A novel progranulin mutation associated with variable clinical
presentation and tau, TDP43 and alpha-synuclein pathology. Brain. 130:
1360–1374
43. Liem MK, Lesnik SA, Vollebregt MJ, Middelkoop HAM, van der Grond J, den
Enden ATJMH (2008) Homozygosity for a NOTCH3 mutation in a 65-year-
old CADASIL patient with mild symptoms. J Neurol. Steinkopff-Verlag 255:
1978–1980
44. Liu X, Jian X, Boerwinkle E (2013) dbNSFP v2.0: a database of human non-
synonymous SNVs and their functional predictions and annotations. Hum
Mutat. 34:E2393–E2402
45. Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, Pottier C et al
(2017) TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal
Dementia Promote Phase Separation and Alter Stress Granule Dynamics.
Neuron 95:808–16.e9
46. Maksemous N, Smith RA, Haupt LM, Griffiths LR (2016) Targeted next
generation sequencing identifies novel NOTCH3 gene mutations in
CADASIL diagnostics patients. Hum Genomics. 10:38
47. Marui W, Iseki E, Kato M, Akatsu H, Kosaka K (2004) Pathological entity of
dementia with Lewy bodies and its differentiation from Alzheimer’s disease.
Acta Neuropathol. 108:121–128
48. McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J (2017)
TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and
ageing. Brain Pathol. 27:472–479
49. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005)
Diagnosis and management of dementia with Lewy bodies: third report of
the DLB Consortium. Neurology. 65:1863–1872
50. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al
(2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing
next-generation DNA sequencing data. Genome Res. 20:1297–1303
51. Meeus B, Verstraeten A, Crosiers D, Engelborghs S, Van den Broeck M,
Mattheijssens M et al (2012) DLB and PDD: a role for mutations in dementia
and Parkinson disease genes? Neurobiol Aging 33:629.e5–629.e18
52. Nagahama Y, Fukui T (2019) Dementia with Lewy bodies presenting as
frontotemporal dementia phenotype. Psychogeriatrics. Available from:
https://doi.org/10.1111/psyg.12405
53. Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF
et al (2013) A multicenter study of glucocerebrosidase mutations in
dementia with Lewy bodies. JAMA Neurol. 70:727–735
54. Ogaki K, Koga S, Heckman MG, Fiesel FC, Ando M, Labbé C et al (2015)
Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk
for Lewy body disorders. Neurology. 85:2016–2025
55. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H et al (2004)
Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology.
63:805–811
56. Peacock ML, Warren JT Jr, Roses AD, Fink JK (1993) Novel polymorphism in
the A4 region of the amyloid precursor protein gene in a patient without
Alzheimer’s disease. Neurology. 43:1254–1256
57. Pickering-Brown SM, Mann DM, Bourke JP, Roberts DA, Balderson D, Burns A
et al (1994) Apolipoprotein E4 and Alzheimer’s disease pathology in Lewy
body disease and in other beta-amyloid-forming diseases. Lancet. 343:1155
58. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al
(2007) PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am J Hum Genet. 81:559–575
59. Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P et al (2007)
Phenotypic variability associated with progranulin haploinsufficiency in
patients with the common 1477C→T (Arg493X) mutation: an international
initiative. Lancet Neurol. 6:857–868
60. Revuelta GJ, Rosso A, Lippa CF (2008) Association Between Progranulin and
β-Amyloid in Dementia With Lewy Bodies. Am J Alzheimers Dis Other
Demen 23:488–493
61. Sekiguchi H, Moriwaki M, Iritani S, Habuchi C, Torii Y, Umeda K et al (2017)
An autopsy case of dementia with Lewy bodies clinically diagnosed to have
a behavioral variant of frontotemporal dementia. Clin Neuropathol.
2017(36):23–30
62. Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir
J et al (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate
microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. 49:
1373–1384
63. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al (2003)
alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841
64. Singleton AB, Wharton A, O’Brien KK, Walker MP, McKeith IG, Ballard CG et al
(2002) Clinical and neuropathological correlates of apolipoprotein E
genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 14:
167–175
65. Stanford PM, Brooks WS, Teber ET, Hallupp M, McLean C, Halliday GM et al
(2004) Frequency of tau mutations in familial and sporadic frontotemporal
dementia and other tauopathies. J Neurol. 251:1098–1104
66. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS et al (2009)
The Human Gene Mutation Database: 2008 update. Genome Med. 1:13
67. Testi S, Malerba G, Ferrarini M, Ragno M, Pradotto L, Mauro A et al (2012)
Mutational and haplotype map of NOTCH3 in a cohort of Italian patients
Orme et al. Acta Neuropathologica Communications             (2020) 8:5 Page 10 of 11
with cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL). J Neurol Sci. 319:37–41
68. Tikka S, Mykkänen K, Ruchoux M-M, Bergholm R, Junna M, Pöyhönen M
et al (2009) Congruence between NOTCH3 mutations and GOM in 131
CADASIL patients. Brain. 132:933–939
69. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA
et al (2013) APOE 4 Increases Risk for Dementia in Pure
Synucleinopathies. JAMA Neurol 70:223–228
70. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-
Moonshine A et al (2013) From FastQ data to high confidence variant calls:
the Genome Analysis Toolkit best practices pipeline. Curr Protoc
Bioinformatics. 43:11.10.1–11.1033
71. van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van
den Akker E et al (2019) A nonsynonymous mutation in PLCG2 reduces the
risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal
dementia, and increases the likelihood of longevity. Acta Neuropathol. 138:
237–250
72. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C.
Genotype–phenotype links in frontotemporal lobar degeneration. Nat Rev
Neurol. 2018;14:363–378. Available from: doi: https://doi.org/10.1038/s41582-
018-0009-8
73. van Swieten JC, Heutink P (2008) Mutations in progranulin (GRN) within the
spectrum of clinical and pathological phenotypes of frontotemporal
dementia. Lancet Neurol. 7:965–974
74. Whiffin N, Minikel E, Walsh R, O’Donnell-Luria AH, Karczewski K, Ing AY et al
(2017) Using high-resolution variant frequencies to empower clinical
genome interpretation. Genet Med. 19:1151–1158
75. Wu Q, Chen M, Buchwald M, Phillips RA (1995) A simple, rapid method for
isolation of high quality genomic DNA from animal tissues. Nucleic Acids
Res. 23:5087–5088
76. Yu C-E, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E et al (2010)
The spectrum of mutations in progranulin: a collaborative study screening
545 cases of neurodegeneration. Arch Neurol. 67:161–170
77. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I et al
(2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and
Lewy body dementia. Ann Neurol. 55:164–173
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Orme et al. Acta Neuropathologica Communications             (2020) 8:5 Page 11 of 11
